Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces the risk of major cardiovascular events, such as heart a

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

Millions of Americans use GLP-1 injections like Ozempic to lose weight. A study is questioning whether they can cause vision loss.